Emerging biomarkers specific to FUS-related ALS include misspliced transcripts (e.g., STMN2, KIF5A), FUS aggregates in CSF and plasma, and stress-granule-associated proteins. This evidence concerns the gene STMN2 and amyotrophic lateral sclerosis.